Select Your Region
Americas
Europe
Africa
Global
Find participating medical centers and current study status in each of them
Find participating medical centers
-
Home
-
Clinical Study Finder
- Yellowstone
How does a new medicine (efmarodocokin alfa) compare to available medicine and placebo – in people with ulcerative colitis
Autoimmune Disorder Inflammatory Bowel Disease (IBD) Ulcerative Colitis
Basic Details
Sponsor
Genentech, Inc. (A part of F. Hoffmann-La Roche Ltd., Switzerland)
Phase
Phase 2
Study Identifier
NCT03558152, GA39925, 2017-002350-36
Condition
Ulcerative Colitis
Official Title
A Phase II, Randomized, Parallel-Group, Double-Blind, Double-Dummy, Placebo-Controlled, Multicenter Study To Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and Compared With Vedolizumab in Patients With Moderate to Severe Ulcerative Colitis
Study Summary
This phase 2, randomized, double-blind, placebo-controlled, parallel-group clinical trial – was done to study “efmarodocokin alfa”, a new medicine for the treatment of patients with ulcerative colitis (UC). This study compared how well efmarodocokin alfa works in comparison to vedolizumab and placebo – when given to people with UC. One hundred and ninety-five people took part at 71 study centers in 16 countries.
Eligibility Criteria
All
≥ 18 Years & ≤ 80 Years
No
Inclusion Criteria
- Diagnosis of UC
- Confirmation of moderately to severely active UC, defined by the Mayo Clinic Score
- Inadequate response, loss of response, or intolerance to prior immunosuppressant treatment (i.e., azathioprine, 6-mercaptopurine, methotrexate, or tumor necrosis factor [TNF] inhibitors [maximum of 2 prior TNF inhibitors]) and/or corticosteroid treatment
- Use of highly effective contraception as defined by the protocol
Exclusion Criteria
- History of psoriasis or psoriatic arthritis; any other inflammatory skin disorders requiring oral corticosteroids, immunosuppressants, or biological therapy within the previous year; or primary sclerosing cholangitis
- History of cancer as defined by the protocol
- Significant uncontrolled comorbidity, such as cardiac, pulmonary, renal, hepatic, endocrine, or gastrointestinal disorders (excluding UC)
- Prior extensive colonic resection, subtotal or total colectomy, or proctocolectomy, or planned surgery for UC
- Diagnosis of indeterminate colitis or granulomatous (Crohn's) colitis or toxic megacolon within 12 months prior to screening
- Suspicion of ischemic colitis, radiation colitis, or microscopic colitis
- Current fistula or history of fistula, pericolonic abscess and stricture (stenosis) of the colon
- History or current evidence of unresectable colonic mucosal dysplasia or history of high-grade colonic mucosal dysplasia
- Prior treatment with UTTR1147A
- Prior treatment with vedolizumab, etrolizumab, natalizumab, efalizumab, or any other anti-integrin agents
- Prior treatment with rituximab
- Use of prohibited therapies, as defined by the protocol, prior to randomization
- Congenital or acquired immune deficiency
- Evidence or treatment of infections or history of infections, as defined by the protocol
The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical study see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.
The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.
Results Disclaimer
Explore related studies
Study results
LPS GA39925 Yellowstone Final Results January 2023 Bulgarian
(PDF, 1.1 MB)
LPS GA39925 Yellowstone Final Results January 2023 English
(PDF, 0.5 MB)
LPS GA39925 Yellowstone Final Results January 2023 Georgian Kartuli ena
(PDF, 1.3 MB)
LPS GA39925 Yellowstone Final Results January 2023 German
(PDF, 1.0 MB)
LPS GA39925 Yellowstone Final Results January 2023 Greek
(PDF, 0.7 MB)
LPS GA39925 Yellowstone Final Results January 2023 Hebrew
(PDF, 0.7 MB)
LPS GA39925 Yellowstone Final Results January 2023 Hungarian
(PDF, 0.8 MB)
LPS GA39925 Yellowstone Final Results January 2023 Italian
(PDF, 1.1 MB)
LPS GA39925 Yellowstone Final Results January 2023 Polish
(PDF, 1.0 MB)
LPS GA39925 Yellowstone Final Results January 2023 Romanian
(PDF, 0.9 MB)
LPS GA39925 Yellowstone Final Results January 2023 Russian
(PDF, 1.0 MB)
LPS GA39925 Yellowstone Final Results January 2023 Serbian
(PDF, 1.0 MB)
LPS GA39925 Yellowstone Final Results January 2023 Spanish Spain
(PDF, 1.0 MB)
LPS GA39925 Yellowstone Final Results January 2023 Spanish USA
(PDF, 1.1 MB)
LPS GA39925 Yellowstone Final Results January 2023 Ukrainian
(PDF, 1.0 MB)
Explore related studies
For the latest version of this information please go to www.forpatients.roche.com